Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Meta-Analysis

医学 HBeAg 乙型肝炎表面抗原 血清转化 α-干扰素 乙型肝炎病毒 α-干扰素 内科学 免疫学 乙型肝炎 胃肠病学 干扰素 病毒载量 抗体 病毒学 病毒
作者
David Wong,Angela M. Cheung,Keith O'Rourke,C. David Naylor,Allan S. Detsky,Jenny Heathcote
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:119 (4): 312-323 被引量:1035
标识
DOI:10.7326/0003-4819-119-4-199308150-00011
摘要

PURPOSE: To determine whether alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic hepatitis B virus (HBV) infection. DATA SOURCES: Randomized controlled studies published in the English literature between January 1966 and June 1992 were identified through a MEDLINE computer search. STUDY SELECTION: Fifteen randomized controlled studies with a total of 837 adult chronic HBV carriers who were positive for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were identified. Studies were included if patients were treated for at least 3 months and followed for at least 6 months after cessation of therapy. RESULTS: Overall, the loss of HBsAg occurred 6% more often in interferon-treated patients than the natural seroconversion seen in controls (7.8% compared with 1.8%, P = 0.001), and the loss of viral replication occurred approximately 20% more often in treated patients than in controls (33% compared with 12% for loss of HBeAg and 37% compared with 17% for the loss of HBV DNA, P = 0.0001) if patients received interferon for 3 to 6 months and were followed for 6 to 12 months. Interferon also had a significant treatment effect on the development of antibodies to HBsAg (anti-HBs), antibodies to HBeAg (anti-HBe), and on the normalization of alanine aminotransferase levels. CONCLUSIONS: Alpha-interferon is effective in terminating viral replication and in eradicating the carrier state in patients with chronic HBV infection who are HBeAg positive when these patients are treated for 3 to 6 months and followed for 6 to 12 months after cessation of therapy. Follow-up studies are required to determine whether interferon reduces the risk for developing cirrhosis or hepatocellular carcinoma.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
搜集达人的应助被lalalall采纳,获得10
刚刚
xiaoXu发布了新的文献求助10
1秒前
Eana发布了新的文献求助10
1秒前
1秒前
酷酷的冷安完成签到,获得积分10
1秒前
kk子的应助被星星采纳,获得10
1秒前
CodeCraft的应助被FiiisH采纳,获得10
2秒前
mlw完成签到,获得积分10
2秒前
FashionBoy的应助被小方采纳,获得10
3秒前
妮妮发布了新的文献求助10
3秒前
无奈冬瓜完成签到,获得积分10
4秒前
5秒前
郑瑞欣完成签到 ,获得积分10
5秒前
一只眠羊发布了新的文献求助10
5秒前
科研通AI6.3的应助被笑笑采纳,获得10
5秒前
wkw发布了新的文献求助10
6秒前
bkagyin的应助被不想看文献采纳,获得10
7秒前
归途完成签到,获得积分10
10秒前
NexusExplorer的应助被zhangxinyi采纳,获得10
10秒前
周周发布了新的文献求助10
10秒前
科研通AI65的应助被ad采纳,获得10
10秒前
12秒前
Mickey完成签到 ,获得积分10
12秒前
abcd_1067完成签到,获得积分10
12秒前
不安的恶天完成签到,获得积分10
12秒前
顾矜的应助被小y同学采纳,获得10
12秒前
12秒前
minmin完成签到 ,获得积分10
13秒前
在水一方的应助被Eana采纳,获得10
14秒前
14秒前
14秒前
妮妮完成签到,获得积分10
14秒前
15秒前
大个的应助被科研通管家采纳,获得10
15秒前
Cr的应助被科研通管家采纳,获得10
15秒前
科研通AI2S的应助被临平吴彦祖采纳,获得10
15秒前
CipherSage的应助被科研通管家采纳,获得10
15秒前
sendou的应助被科研通管家采纳,获得30
15秒前
Jasper的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183601
求助须知:如何正确求助?哪些是违规求助? 9572875
关于积分的说明 21827816
捐赠科研通 7780716
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558197
邀请新用户注册赠送积分活动 2480485